Sickle Cell Disease Treatment Market Summary

The global sickle cell disease treatment market size was valued at USD 2,758.5 million in 2023 and is projected to reach USD 7,422.4 million by 2030, registering a CAGR of 15.7% between 2024 and 2030. The growth of this market is primarily driven by increasing disease awareness among patients and healthcare providers, continuous advancements in medical research and technology, and the rising need for effective treatment options to improve patient outcomes and quality of life.

Government initiatives, supportive healthcare policies, and strategic collaborations between pharmaceutical companies and research institutions are further boosting market expansion. These efforts are facilitating innovation in therapies, clinical trials, and drug development. However, the COVID-19 pandemic disrupted healthcare systems worldwide, limiting access to diagnostic services and treatment facilities. This negatively affected individuals with hemoglobinopathies, including sickle cell disease, highlighting the need for resilient healthcare structures.

The increasing prevalence of hemoglobinopathies is expected to accelerate market demand throughout the forecast period. Global migration and population movement are contributing to the introduction of sickle cell disease into regions where it was previously uncommon. For instance, prevalence rates of the sickle cell trait can reach up to 40% in regions such as central India, eastern Saudi Arabia, and sub-Saharan Africa, while remaining significantly lower in most European countries.

Key Market Trends & Insights

• North America led the global market in 2023, accounting for the largest revenue share of 37.87%. This dominance is attributed to strong healthcare infrastructure, ongoing research initiatives, and wide availability of treatment facilities.
• The Asia Pacific region is anticipated to grow at an exponential pace during the forecast period, fueled by increasing healthcare investment, a rising patient pool, and greater government emphasis on managing genetic disorders.
• Based on treatment, the blood transfusion segment held the largest market share of 48.45% in 2023, driven by its effectiveness in managing complications and improving the quality of life in patients.
• In terms of type, the hospital segment accounted for the largest share of 60.40% of the global sickle cell disease treatment market in 2023, owing to the availability of specialized care, advanced facilities, and trained medical professionals.

Order a free sample PDF of the Sickle Cell Disease Treatment Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 2,758.5 Million
• 2030 Projected Market Size: USD 7,422.4 Million
• CAGR (2024-2030): 15.7%
• North America: Largest market in 2023

Key Companies & Market Share Insights

Key players are adopting strategies such as new product developments, approvals, collaborations, acquisitions, and partnerships to strengthen their market position.

• In April 2023,Editas Medicine, Inc. received Orphan Drug Designation from the U.S. FDA for its EDIT-301 for treating SCD.
• In April 2023,Bluebird Bio submitted an approval application to U.S. FDA for its gene therapy drug for SCD treatment.

Key Players

• Novartis AG  
• Bluebird Bio, Inc.
• Pfizer Inc.  
• Bristol-Myers Squibb Company
• GlycoMimetics
• Emmaus Medical, Inc.
• Graphite Bio, Inc.
• CRISPR Therapeutics

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global sickle cell disease treatment market is poised for robust growth due to increasing awareness, supportive policies, and continuous advancements in treatment solutions. While challenges such as the COVID-19 pandemic temporarily disrupted services, ongoing government support and collaborative efforts between healthcare providers and pharmaceutical companies are expected to drive innovation and expand access to therapies. North America currently leads the market, but the Asia Pacific region is projected to witness the fastest growth, supported by rising investments and a growing patient base. Overall, the demand for effective, accessible, and advanced treatments will continue to shape the market’s expansion.